Mehabe score: 4 G Factor: 2 Piotski Score: 7 The stock has a rating SELL. The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 2 and Piotski score of 7. Site:PREVEST Main Symbol:PREVEST
Stock trades at 348.0, below its 50dma 364.51. However it is trading above its 200dma 275.96. The stock remains weak in the short term due to near term bearish momentum. However overall bullish structure remains intact. Price action will further build up as it moves above its dma50, currently situated at 364.51.
The 52 week high is at 478.15 and the 52week low is at 170.65
Price Chart
P/E Chart
Sales and Margin
Strengths
– is almost debt free.
Weakness
– Stock is trading at 18.38 times its book value
-Though the company is reporting repeated profits, it is not paying out dividend
Competition
– The industry trades at a mean P/E of 33.0x. Max Healthcare trades at the industry’s max P/E of 178.66x. PREVEST trades at a P/E of 56.2x
– Industry’s mean G-Factor is 3.8 while the mean Piotski score is 9.0. PREVEST has a G-Factor of 2 and Piotski scoreof 7.
– Average 1 month return for industry is -11.7%. The max 1- month return was given by Narayana Hrudaya: a return of 2.97 %
Quarterly Results
.
Company reported operating profit of Rs 4.6 cr for period ended Dec 2021 and operating profit margin at 41.4 % for same period.
The EPS for quarter ended Dec 2021 is Rs 3.12 compared to Rs 0 for previous quarter ended Unnamed: 0.
The EPS for quarter ended Dec 2021 is Rs 3.12 compared to Rs 0 for previous quarter ended Unnamed: 0.
Profit & Loss Statement
Profit&Loss Comments
Company reported sales of Rs 27.38 cr for period ended Mar 2021 vis-vis sales of Rs 22.59 cr for the period ended Mar 2020, a healthy growth of 17.5%.
Operating margins expanded to 29.25% for period ended Mar 2021 vis-vis 22.97% for period ended Mar 2020, expansion of 628.0 bps.
Net Profit reported at Rs 7.44 cr for period ended Mar 2021 vis-vis sales of Rs 5.01 cr for the period ended Mar 2020, rising 0%.
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
CashFlow from operating activities was positive.
CashFlow from operating activities: Rs 8.61 cr for period ended Mar 2021 vis-vis Rs 4.73 cr for period ended Mar 2020
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The company has improved its Return on Equity (RoE) metric. The RoE on Last Year basis was 39.0% compared to 0% over the last 3 Years. – The stock has given a return of % on a 1 Year basis vis-vis a return of % over the last 3 Years. – The compounded sales growth on a TTM bassis is 21% vis-vis a compounded sales growth of % over the last 3 Years. – The compounded profit growth on a TTM basis is 49% vis-vis a compounded profit growth of % over the last 3 Years.
Ratios
Shareholding Pattern
Conclusion
– is almost debt free. – Stock is trading at 18.38 times its book value
-Though the company is reporting repeated profits, it is not paying out dividend
Fundamentally, the stock remains weak. The business fundamentals are on shaky ground. Weak near term results have dampened and questioned business drivers. We suggest to wait for a upturn in business performance.
Technically, the stock reflects the poor fundamentals. The stock remains below its 50 DMA 364.51 and is trading at 348.0. It has shown near term lack of bullish momentum. We suggest to observe price action. However as investors, who like to avoid timing the markets, we suggest to avoid the stock
